Clearmind Medicine (CMND) news
Recent news
Clearmind Medicine - deal valued at $2.50 mln for 51% majority stake
AInvest Wire · Aug 3, 2026Clearmind Medicine - to extend $1.50 mln loan at 4% interest, repayable in two years
AInvest Wire · Aug 3, 2026Clearmind Medicine reports positive retention results for intranasal formulation of its psychedelic-based neuroplastogen Meai
AInvest Wire · Jul 16, 2026Clearmind Medicine Inc.: Clearmind Medicine in pact to examine MEAI in combination, sequencing with tirzepatide vs blockbuster
Clearmind Medicine Inc. (Nasdaq: CMND) has announced plans to explore the potential of its proprietary compound MEAI in combination with or in sequence with tirzepatide, a dual GLP-1/GIP receptor agonist developed by Eli Lilly and currently one of the most widely prescribed weight loss medications.…
AInvest Wire · May 18, 2026SciSparc and Clearmind Medicine reflect on successful collaboration in 2023 planning to upgrade a wide range of psychedelic-based treatments
SciSparc and Clearmind Medicine reflect on successful collaboration in 2023 planning to upgrade a wide range of psychedelic-based treatments SciSparc and Clearmind Medicine have been collaborating in the field of psychedelic-based treatments and have recently reflected on their successful…
AInvest Wire · Jan 4, 2024Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.